Savara (SVRA) said late Wednesday it started a rolling submission of a biologics license application, or BLA, to the US Food and Drug Administration for Molbreevi, aimed at potentially treating autoimmune Pulmonary Alveolar Proteinosis, a rare lung disease.
The clinical-stage biopharmaceutical company said it plans to finalize the BLA submission by the end of Q1 2025 and intends to seek priority review.
Shares of Savara were up 0.3% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。